References
- Duijkers IJM , Klipping C. Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecol Endocrinol 2010;26:152–60.
- Catteau-Jonard S , Dewailly D. Anti-Mullerian hormone and polycystic ovary syndrome. Gynecol Obstet Fertil 2011;39:514–7.
- Klein DA , Poth MA. Amenorrhea: an approach to diagnosis and management. Am Fam Physician 2013;87:781–8.
- Nyboe Andersen A , Nelson SM , Fauser BC , et al . Individualized vs. conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase-3 noninferiority trial. Fertil Steril 2017;107:387–96.e4.
- Arce JC , Klein BM , La Marca A. The rate of high ovarian response in women identified at risk by a high-serum AMH level is influenced by the type of gonadotropin. Gynecol Endocrinol 2014;30:444–50.
- Platteau P , Andersen AN , Balen A , et al . Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod 2006;21:1798–804.
- Toftager M , Bogstad J , Bryndorf T , et al . Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod 2016; 31:1253–64.
- Humaidan P , Ejdrup Bredkjaer H , Westergaard LG , Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010;93:847–54.
- Nelson SM , Yates RW , Lyall H , et al . Anti-Mu¨llerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867–75.
- Yates AP , Rustamov O , Roberts SA , et al . Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod 2011;26:2353–62.
- Salmassi A , Mettler L , Hedderich J , et al . Cut-off levels of anti-mullerian hormone for the prediction of ovarian response, in vitro fertilization outcome and ovarian hyperstimulation syndrome. Int J Fertil Steril 2015;9:157–67.
- Kamel A , Ramadan W , Hussein AM , et al . Can AMH levels predict the need for increased medication during IVF/ICSI in PCOS women? J Matern Fetal Neonatal Med 2018;31:32–8.
- Popovic-Todorovic B , Loft A , Bredkjaeer HE , et al . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors vs. a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Hum Reprod 2003;18:2275–8.
- Olivennes F , Howies CM , Borini A , et al . Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 2011;22:S73–S82.
- Verberg MF , Eijkemans MJ , Macklon NS , et al . The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. Hum Reprod Update 2009;15:5–12.
- Iliodromiti S , Lan VT , Tuong HM , et al . Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study. J Ovarian Res 2013;6:93.
- Vembu R , Reddy NS. Serum AMH level to predict the hyper response in women with PCOS and Non-PCOS undergoing controlled ovarian stimulation in ART. J Hum Reprod Sci 2017;10:91–4.
- Ocal P , Sahmay S , Cetin M , et al . Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet 2011;28:1197–203.
- Stracquadanio M , Ciotta L , Palumbo MA. Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women. Gynecol Endocrinol 2017;1–6. doi: 10.1080/09513590.2017.1381838. [Epub ahead of print]
- Fraissinet A , Robin G , Pigny P , et al . Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod 2017;32:1716–22. doi: 10.1093/humrep/dex239.
- Magnusson Å , Nilsson L , Oleröd G , et al . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial. Hum Reprod 2017;32:811–9.